Summit Therapeutics

Summary
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

History

Summit Therapeutics was founded in 2003 and is based in Oxford, United Kingdom. The company has multiple subsidiaries worldwide, including those in the US, Europe, and Canada. The company's focus is on discovering, developing, and ultimately commercialising small molecule medicines for the treatment of infectious diseases and other conditions with unmet needs. The company’s lead product is ridinilazole, which is in clinical development to treat Clostridioides difficile infection.


Mission
Summit Therapeutics is dedicated to discovering, developing and commercializing novel medicines to address unmet medical needs.

Vision
Summit Therapeutics’ vision is to become a major player in the development and commercialisation of innovative medicines in areas of unmet medical need.

Key Team

Mr. Campbell Hair (Head of HR?)

Prof. Dame Kay Davies DBE, FRS CBE (Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor)

Mr. Ankur Dhingra (Chief Financial Officer)

Ms. Michelle Avery (Director of Investor Relations)

Dr. Elaine Carla Stracker J.D., Ph.D. (Head of Compliance? & Gen. Counsel)

Dr. Anne Heatherington (Head of Clinical Devel. and Quantitative Sciences)

Ms. Divya Chari (Head of Global Clinical Operations)


Recognition and Awards
Summit Therapeutics have achieved several awards, including the Red Herring Europe 100 Top Private Companies Award, the EY Entrepreneur of the Year Award, and the HealthTech and MedTech category in the Deloitte Technology Fast 50 award. They have a strong commitment to patient safety and excellence in R&D that has been recognised by numerous awards.

References
Summit Therapeutics
Leadership team

Mr. Robert W. Duggan (CEO & Exec. Chairman)

Dr. Mahkam Zanganeh D.D.S., M.B.A., MBA (Co-CEO, Pres & Director)

Dr. Urte Gayko Ph.D. (Head of Regulatory Affairs, Quality Assurance & Safety and Director)

Products/ Services
Biotechnology, Health Care, Medical Device, Therapeutics
Number of Employees
100 - 500
Headquarters
Abingdon, Oxfordshire, United Kingdom
Established
2003
Company Registration
SEC CIK number: 0001599298
Revenue
500K - 2M
Traded as
SMMT
Social Media
Fri Mar 01 2024
About

businessabc offers a global business, SMEs wiki directory blockchain, NFTs, AI powered marketplace for businesses worldwide.

Follow Us
Produced by
In collaboration with
Logo

Copyright 2023 © businessabc powered by ztudium